Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (3) , 986-991
Abstract
No abstract availableKeywords
Funding Information
- NHMRC (APP1027369, APP1084083, APP1083131, APP1047759)
- Australian Research Council (DP130100629, CE140100011)
- Queensland Government
- University of Queensland
This publication has 21 references indexed in Scilit:
- Antagonism of Protease-Activated Receptor 2 Protects against Experimental ColitisThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Protease‐activated receptor 2, rather than protease‐activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritisArthritis & Rheumatism, 2011
- Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)British Journal of Pharmacology, 2011
- Structure, function and pathophysiology of protease activated receptorsPharmacology & Therapeutics, 2011
- Novel Agonists and Antagonists for Human Protease Activated Receptor 2Journal of Medicinal Chemistry, 2010
- PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cellsBiochemical and Biophysical Research Communications, 2008
- Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2006
- 2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 AgonistThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Molecular Cloning and Functional Expression of the Gene Encoding the Human Proteinase‐Activated Receptor 2European Journal of Biochemistry, 1995
- Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptorChemistry & Biology, 1994